"Our Doctors are board-certified in hematology, oncology and internal medicine and treat the entire spectrum of cancer and blood diseases. We specialize in urologic, gastrointestinal and neurologic malignancies. We offer a large multi-disciplinary team at St. Luke’s which includes experts in pathology, radiology, radiation oncology, internal medicine, surgery, pulmonology, palliative care and genetic testing."

During the past decade, Kansas City Oncology and Hematology Group conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kansas City Oncology and Hematology Group" #1 sponsor was "Chiron Corporation" with 4 trials, followed by "Abbott" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "University of Nebraska" with 2 trials sponsored and "Astellas Pharma Inc" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kansas City Oncology and Hematology Group" #1 collaborator was "Bayer" with 1 trials as a collaborator, "Canadian Cancer Trials Group" with 1 trials as a collaborator, "National Cancer Institute (NCI)" with 1 trials as a collaborator and "OSI Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Kansas City Oncology and Hematology Group" are "Breast Cancer" (4 trials), "Lymphoma, Non-Hodgkin" (3 trials), "Adenocarcinoma" (2 trials), "Colorectal Neoplasms" (2 trials) and "Pancreatic Cancer" (2 trials). Many other conditions were trialed in "Kansas City Oncology and Hematology Group" in a lesser frequency.

Most popular intervention types in "Kansas City Oncology and Hematology Group" are "Drug" (16 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Recombinant Human Interleukin-2 and Rituximab" (2 trials), "tezacitabine" (2 trials), "5-fluorouracil" (1 trials), "ABT-510 - Thrombospondin-1 Mimetic" (1 trials) and "ABT-510/Thrombospondin-1 mimetic" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kansas City Oncology and Hematology Group" are 15 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Kansas City Oncology and Hematology Group". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Kansas City Oncology and Hematology Group, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Kansas City Oncology and Hematology Group, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".